Panitumumab is a humanized monoclonal antibody that binds to epidermal growth factor receptor (EGFR), which is often overexpressed in colorectal cancers. Combination of Panitumumab and EGFR reduces cell proliferation therefore inhibits colorectal cancers. It was approved for the treatment of EGFR-expressing metastatic colorectal cancer.